Ibrutinib: A first in class covalent inhibitor of Bruton's tyrosine kinase

Future Oncology

Volumn 10, Issue 6, 2014, Pages 957-967

  Davids, Matthew S ^a   Brown, Jennifer R ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

B cell receptor; BTK; CLL; ibrutinib; kinase; lymphocytosis; MCL; NHL

Indexed keywords

BENDAMUSTINE; BRUTON TYROSINE KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; IBRUTINIB; MONOCLONAL ANTIBODY; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHRONIC LYMPHATIC LEUKEMIA; CONSTIPATION; CONTUSION; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DYSPEPSIA; FATIGUE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOCYTE; LYMPHOMA; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; MULTIPLE MYELOMA; MUSCLE SPASM; MYALGIA; NAUSEA; NONHUMAN; PAIN; PERIPHERAL EDEMA; PHARMACODYNAMICS; PNEUMONIA; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; URINARY TRACT INFECTION; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG SCREENING; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PHASE 1 CLINICAL TRIAL (TOPIC); TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; COMBINED MODALITY THERAPY; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84903195046     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.51     Document Type: Article

References (33)

1. de Weers M, Mensink RG, Kraakman ME, Schuurman RK, Hendriks RW. Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: Identification of a mutation which affects the same codon as is altered in immunodeficient xid mice. Hum. Mol. Genet. 3(1), 161-166 (1994
2. Herman SE, Gordon AL, Hertlein E et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23), 6287-6296 (2011
3. Byrd JC, Furman RR, Coutre SE et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(1), 32-42 (2013
4. Wang ML, Rule S, Martin P et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369(6), 507-516 (2013
5. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010
6. Fischer K, Cramer P, Busch R et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 30(26), 3209-3216 (2012
7. Eichhorst B, Fink AM, Busch RB et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): Results of a planned interim analysis of the CLL10 trial, an international, randomized study of The German CLL Study Group (GCLLSG). Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA, 7-10 December 2013
8. Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, Phase 3 non-inferiority trial. Lancet 381(9873), 1203-1210 (2013
9. Goede V, Fischer K, Busch R et al. Head-To-head comparison of obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus clb in patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities): Final stage 2 results of the CLL11 trial. Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA, 7-10 December 2013
10. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011
11. Honigberg LA, Smith AM, Sirisawad M et al. The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc. Natl Acad. Sci. USA 107(29), 13075-13080 (2010
12. Dubovsky JA, Beckwith KA, Natarajan G et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122(15), 2539-2549 (2013
13. Advani RH, Buggy JJ, Sharman JP et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J. Clin. Oncol. 31(1), 88-94 (2013
14. Ponader S, Chen SS, Buggy JJ et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5), 1182-1189 (2012
15. O'Brien S, Furman RR, Coutre SE et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: An open-label, multicentre, Phase 1b/2 trial. Lancet Oncol. 15(1), 48-58 (2013
16. Wilson WH, Gerecitano JF, Goy A et al. The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-Cell lymphoma (DLBCL): Interim results of a multicenter, open-label, Phase 2 study. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7-10 December 2013 (Abstract 686
17. Treon SP, Tripsas CK, Yang, G et al. A prospective multicenter study of the bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory waldenstrom's macroglobulinemia. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7-10 December 2013 (Abstract 251
18. Fowler NH, Advani RH, Sharman JP et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma. Presented at: The 55 ASH® Annual Meeting and Exopsition. GA, USA, 8-11 2012 (Abstract 156
19. Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369(13), 1278-1279 (2013
20. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, MacEwan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell. Signal. 25(1), 106-112 (2013
21. Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ. Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia. Blood 123(8), 1229-1238 (2013
22. Hallek M, Cheson BD, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111(12), 5446-5456 (2008
23. Cheson BD, Byrd JC, Rai KR et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J. Clin. Oncol. 30(23), 2820-2822 (2012
24. Chang B, Furman RR, Zapatka M et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL). Presented at: ASCO Annual Meeting. IL, USA, 31 May-4 June 2013 (Abstract 7014
25. Burger JA, Landau D, Hoellenriegel J et al. Clonal evolution in patients with chronic lymphocytic leukemia (CLL) developing resistance to BTK inhibition. Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA 7-10 December 2013 (Abstract 866
26. Burger JA, Keating MJ, Wierda WG et al. Ibrutinib in combination with rituximab (iR) is well tolerated and induces a high rate of durable remissions in patients with high-risk chronic lymphocytic leukemia (CLL): New, updated results of a Phase II trial in 40 patients. Presented at: The 55th ASH® Annual Meeting and Exposition. LA, USA 7-10 December 2013 (Abstract 7014
27. Jaglowski SM, Jones JA, Flynn JM et al. A Phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. Presented at: 2012 ASCO Annual Meeting. IL, USA, 1-5 June 2012 (Abstract 6508
28. Kohrt H, Sagiv-Barfi I, Rafiq S et al. Ibrutinib (PCI-32765) antagonizes rituximab-dependent NK-cell mediated cytotoxicity. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7-10 December 2013 (Abstract 373
29. Bottcher S, Ritgen M, Fischer K et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 30(9), 980-988 (2012
30. Brown JR, Barrientos JC, Barr PM et al. Ibrutinib in combination with bendamustine and rituximab is active and tolerable in patients with relapsed/refractory CLL/SLL. Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7-10 December 2013 (Abstract 525
31. A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma. www.clinicaltrials.gov/ct2/show/ NCT01776840
32. Younes A, Flinn I, Berdeja J et al. Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): Updated results from a Phase 1b study in treatment-naive patients with CD20-positive B-Cell non-Hodgkin's lymphoma (NHL). Presented at: The 55 ASH® Annual Meeting and Exopsition. LA, USA, 7-10 December 2013 (Abstract 852
33. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK. Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 108(8), 2596-2603 (2006.